Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells*
暂无分享,去创建一个
Shuang Huang | Shuang Huang | J. Chun | C. Mahanivong | D. Bian | Jerold Chun | Dafang Bian | Chitladda Mahanivong | Hongbin Li | Xiaoqin Ye | X. Ye | Hongbing Li
[1] G. Mills,et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. , 2003, Cancer research.
[2] Y. Saga,et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin , 2003 .
[3] G. Mills,et al. Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer , 2000, Annals of the New York Academy of Sciences.
[4] E. Lengyel,et al. Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*) , 1995, The Journal of Biological Chemistry.
[5] A. Hall,et al. Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-Type Plasminogen Activator Receptor Binding to Vitronectin , 2001, The Journal of cell biology.
[6] P. Dettmar,et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.
[7] W. Kolch,et al. The Raf‐1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments , 2000, The FASEB Journal.
[8] A. Villa,et al. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. , 1999, Blood.
[9] Y. Hirashima,et al. Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling Pathways* , 2001, The Journal of Biological Chemistry.
[10] G. V. Vande Woude,et al. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network , 1996, Molecular and cellular biology.
[11] E. Goetzl,et al. Lysophospholipid mediators of immunity and neoplasia. , 2002, Biochimica et biophysica acta.
[12] M Markman,et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.
[13] Chen-Yong Lin,et al. Inhibition of Tumor Invasion by Genomic Down-regulation of Matriptase through Suppression of Activation of Receptor-bound Pro-urokinase* , 2004, Journal of Biological Chemistry.
[14] N. Harbeck,et al. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function , 1998, FEBS letters.
[15] G. Johnson,et al. Direct Interaction between Ras and the Kinase Domain of Mitogen-activated Protein Kinase Kinase Kinase (MEKK1) (*) , 1995, The Journal of Biological Chemistry.
[16] K. Okada,et al. Co-localization of urokinase and its receptor on established human umbilical vein endothelial cell. , 1999, Cell structure and function.
[17] D. Collen. The Plasminogen (Fibrinolytic) System , 1999, Thrombosis and Haemostasis.
[18] Shuang Huang,et al. Rac1-MKK3-p38-MAPKAPK2 Pathway Promotes Urokinase Plasminogen Activator mRNA Stability in Invasive Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.
[19] M. Schmitt,et al. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice , 1995, Clinical & Experimental Metastasis.
[20] E. Lengyel,et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] R. Kumar,et al. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. , 2001, Cancer research.
[22] Zhimin Lu,et al. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases , 1999, Oncogene.
[23] Michael S. Pepper,et al. Membrane proteases in focus , 1994, Nature.
[24] B. Giepmans,et al. The ins and outs of lysophosphatidic acid signaling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] C. Borgfeldt,et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI‐1) , 2001, International journal of cancer.
[26] S. Rabbani,et al. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.
[27] F. Imamura,et al. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA) , 1999, International journal of cancer.
[28] J. Sedivy,et al. Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[29] G. Mills,et al. Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* , 2004, Journal of Biological Chemistry.
[30] R. Gertz,et al. The significance of urokinase‐type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer , 1995, Cancer.
[31] G. Mills,et al. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] Jing Chen,et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] G. Nemerow,et al. Urokinase Plasminogen Activator/Urokinase-specific Surface Receptor Expression and Matrix Invasion by Breast Cancer Cells Requires Constitutive p38α Mitogen-activated Protein Kinase Activity* , 2000, The Journal of Biological Chemistry.
[34] Shuang Huang,et al. Chemoattractant-stimulated NF-κB Activation Is Dependent on the Low Molecular Weight GTPase RhoA* , 2001, The Journal of Biological Chemistry.
[35] S. Miyamoto,et al. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. , 2003, Cancer letters.
[36] C. Gondi,et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis , 2003, Oncogene.
[37] J. Chun,et al. Lysophosphatidic acid as a novel cell survival/apoptotic factor. , 2002, Biochimica et biophysica acta.
[38] G. Mills,et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. , 2001, Journal of the National Cancer Institute.
[39] O. Kranenburg,et al. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists , 2001, Oncogene.
[40] G. Bren,et al. The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B , 1996, Journal of virology.
[41] G. Nemerow,et al. Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.
[42] A. Morris,et al. Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells Published, JLR Papers in Press, July 1, 2003. DOI 10.1194/jlr.M300188-JLR200 , 2003, Journal of Lipid Research.
[43] Yan Xu,et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. , 2001, Gynecologic oncology.
[44] John Calvin Reed,et al. Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.
[45] B. Giepmans,et al. Lysophosphatidic acid: mitogen and motility factor. , 2003, Biochemical Society transactions.
[46] A. Krüger,et al. High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread , 2002, FEBS letters.
[47] Gordon B Mills,et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. , 2002, Biochimica et biophysica acta.
[48] M. Schmitt,et al. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. , 1999, European journal of biochemistry.
[49] L. Matrisian,et al. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis , 1995, Cancer and Metastasis Reviews.
[50] J. Oh,et al. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.
[51] G. Mills,et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] L. Guerrini,et al. NF‐κB‐mediated regulation of urokinase gene expression by PMA and TNF‐α in human A549 cells , 1996 .
[53] R. Lefkowitz,et al. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades , 2001, Oncogene.
[54] L. Liotta,et al. General mechanisms of metastasis , 1997, Cancer.
[55] S. Demo,et al. ralGDS family members interact with the effector loop of ras p21 , 1994, Molecular and cellular biology.
[56] A. Kusch,et al. Urokinase Stimulates Human Vascular Smooth Muscle Cell Migration via a Phosphatidylinositol 3-Kinase-Tyk2 Interaction* , 2000, The Journal of Biological Chemistry.
[57] J. Weiner,et al. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[58] J. Chun,et al. Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2 , 2002, Molecular and Cellular Biology.
[59] D. Morrison,et al. Characterization of Raf-1 Activation in Mitosis* , 1999, The Journal of Biological Chemistry.
[60] G. Rice,et al. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. , 2004, Gynecologic oncology.
[61] E. Goetzl,et al. Lysophosphatidic Acid Receptor-Selective Effects on Jurkat T Cell Migration Through a Matrigel Model Basement Membrane1 , 2001, The Journal of Immunology.
[62] Shuang Huang,et al. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway , 2004, Cancer Research.
[63] G. Nemerow,et al. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. , 1997, Immunity.
[64] E. Rozengurt,et al. Cooperation of Gq, Gi, and G12/13 in Protein Kinase D Activation and Phosphorylation Induced by Lysophosphatidic Acid* , 2003, The Journal of Biological Chemistry.
[65] J. Wood,et al. Specific keynote: molecular determinants of angiogenesis in ovarian cancer. , 2003, Gynecologic oncology.
[66] J. Chun,et al. Lysophospholipid G Protein-coupled Receptors* , 2004, Journal of Biological Chemistry.
[67] D. Fishman,et al. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. , 2001, Cancer research.
[68] F. Blasi. Proteolysis, Cell Adhesion, Chemotaxis, and Invasiveness Are Regulated by the u-PA-u-PAR-PAI-1 System , 1999, Thrombosis and Haemostasis.
[69] L. Liotta,et al. Molecular aspects of tumor cell invasion and metastasis , 1993, Cancer.
[70] M. Wigler,et al. Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS , 1996, Science.
[71] F. Bertrand,et al. Insulin Activates Nuclear Factor κB in Mammalian Cells through a Raf-1-mediated Pathway (*) , 1995, The Journal of Biological Chemistry.
[72] S. Nakano,et al. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells , 2004, Clinical & Experimental Metastasis.
[73] G. Mills,et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] R. Kimmig,et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] M. Wigler,et al. Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.
[76] T. Nakamura,et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. , 1998, The American journal of pathology.